JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
Go back to JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis| (NASDAQ: ROIV) | Delayed: 38.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.99 | 52 Week High | $ | |||
| Open | $38.99 | 52 Week Low | $ | |||
| Day High | $38.99 | P/E | N/A | |||
| Day Low | $38.99 | EPS | $ | |||
| Volume | 2,507 | |||||
| (NASDAQ: ROIVW) | Delayed: 2.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.75 | 52 Week High | $ | |||
| Open | $25.55 | 52 Week Low | $ | |||
| Day High | $2.75 | P/E | N/A | |||
| Day Low | $2.75 | EPS | $ | |||
| Volume | 555 | |||||
